Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Holdings Lifted by Pier 88 Investment Partners LLC

Pier 88 Investment Partners LLC lifted its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 121.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 113,700 shares of the company’s stock after acquiring an additional 62,340 shares during the quarter. Pier 88 Investment Partners LLC owned 0.19% of Pyxis Oncology worth $376,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Vestal Point Capital LP acquired a new position in shares of Pyxis Oncology in the 4th quarter valued at $792,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Pyxis Oncology in the first quarter worth about $351,000. Cable Car Capital LLC purchased a new position in shares of Pyxis Oncology in the fourth quarter worth approximately $111,000. Decheng Capital LLC purchased a new position in shares of Pyxis Oncology in the fourth quarter worth approximately $588,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology during the first quarter valued at approximately $59,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $3.50 on Friday. The firm has a market cap of $206.11 million, a price-to-earnings ratio of -2.57 and a beta of 1.28. Pyxis Oncology, Inc. has a 1 year low of $1.35 and a 1 year high of $6.85. The business has a fifty day simple moving average of $3.44 and a 200 day simple moving average of $4.13.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. On average, sell-side analysts forecast that Pyxis Oncology, Inc. will post -1.07 EPS for the current year.

Analyst Ratings Changes

PYXS has been the topic of several research analyst reports. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $9.00.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.